Long-term annual sales outlook
RecordSTO-1V3Z865SSN-2HW20Y3VVR-25RJ76
Global · 2031
GSK projects long-term annual sales outlook at more than 40 billion GBP in 2031.
Long-term annual sales outlook: every country and year, and how it is measured
- Publisher
- GSK
- Authority tier
- T3 Research
- Locator
- Growth outlooks:
- Retrieved
- 17 Sep 2026
- Status
- Verified
What the source says
On track for 2031 sales outlook of more than £40 billion; Accelerating growth from 2031 onwards
Checked: the figure 40 billion GBPis stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
GSK. (2031). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_1V3Z865SSN2HW20Y3VVR25RJ76
Other formats: MLA, Chicago, BibTeX
- MLA
- GSK. "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026." 2031, https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_1V3Z865SSN2HW20Y3VVR25RJ76.
- Chicago
- GSK. "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026." 2031. https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_1V3Z865SSN2HW20Y3VVR25RJ76.
- BibTeX
- @misc{gsk2031long25rj76, author = {{GSK}}, title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026}, year = {2031}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_1V3Z865SSN2HW20Y3VVR25RJ76}, note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- GSK · homepage ↗
- Authority tier
- Tier 3 · Research and companies
- Report
- GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
- Type
- Press release
- Published
- —
- Locator
- Growth outlooks:
- Retrieved
- 17 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification
- Status
- Verified
- Review protocol
- Editorial review
- Checked on
- 17 September 2026
- Last revision
- 27 September 2026
- Permanent URL
- /stat/stat_1V3Z865SSN2HW20Y3VVR25RJ76